PEDIATRICS Vol. 98 No. 4 October 1996, pp. 799-800
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Durand, M.
Right arrow Articles by McEvoy, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Durand, M.
Right arrow Articles by McEvoy, C.

Letter To The Editor

Manuel Durand MD1, Smeeta Sardesai MD1, and Cindy McEvoy MD2

1 LAC-USC Medical Center, USC School of Medicine, Los Angeles, CA
2 Sacred Heart Hospital, University of Florida, Pensacola, FL

We thank Dr Zecca and associates for their interest in our paper.1 Their concerns regarding possible cardiac side effects during steroid therapy in very low birth weight (VLBW) infants are quite appropriate and, we feel, further emphasize the benefits of an "early" (mean postnatal age, 9 to 10 days) and "short" (7 days) course of dexamethasone therapy for this group of infants at risk for long-term pulmonary morbidities. The prior studies they have referenced2-5 and another recent study6 applied longer courses of steroid therapy (up to 42 days) to infants with well-established chronic lung disease (CLD).